IGF-1 LR3
Also known as: DES(1-3) IGF-1 variant, IGF-LR3, IGF1-LR3, Insulin-like Growth Factor-1 Long R3, Long R3 IGF-1, Long-R3-IGF-1
Source IGF-1 LR3 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Long-acting synthetic analog of insulin-like growth factor 1 with reduced IGFBP binding and extended biological activity; not approved for human therapeutic use
Mechanism of Action
IGF-1 receptor agonist with extended half-life due to arginine substitution at position 3 and 13 amino acid N-terminal extension; promotes cell growth, proliferation, and survival via PI3K/AKT and MAPK pathways
Routes of Administration
Goals & Uses
- fat lossBody CompositionLow
- anti-agingLongevityLow
- tissue repairRecoveryLow
- muscle hypertrophyPerformance EnhancementLow
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- diabetes mellitusMetabolicModerate
Adverse Effects
- organomegalyStructuralUncommon
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Injection site reactionsLocalCommon
- acromegalic featuresEndocrineUncommon
- cancer progressionOncologicUnknown
- water retentionMetabolicCommon
Drug Interactions
- InsulinHighMay increase risk of low blood sugar
- GlucocorticoidsLow
- Growth hormoneModerate
Population Constraints
- individuals with IGF-1 hypersensitivityImmunologicAbsolute
- Pediatric patientsAgeAbsolute
- patients with active cancer historyDiseaseRelative
- Elderly with cardiovascular diseaseComorbidityRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization by EMA
- United StatesUnapprovedNot approved by FDA; not a legal dietary supplement; enforcement action against marketed products
- United KingdomUnapprovedMHRA does not recognize as medicinal product; controlled under Psychoactive Substances Act concerns
Not approved by FDA, EMA, or other major regulatory bodies; sold as research chemical; prohibited in competitive sports by WADA
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is IGF-1 LR3?
Long-acting synthetic analog of insulin-like growth factor 1 with reduced IGFBP binding and extended biological activity; not approved for human therapeutic use
What is IGF-1 LR3 used for?
IGF-1 LR3 is educationally associated with: fat loss, anti-aging, tissue repair, muscle hypertrophy. Educational only — not medical advice.
How is IGF-1 LR3 administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of IGF-1 LR3?
Reported adverse effects include: organomegaly, Hypoglycemia, Injection site reactions, acromegalic features, cancer progression, water retention. This list is not exhaustive — consult a qualified clinician.
Who should avoid IGF-1 LR3?
Recorded contraindications: Active malignancy, Pregnancy, diabetes mellitus. Consult a qualified clinician before use.